R&D News | pharmaphorum

News

Novo-backed $61m fundraising helps F2G prep for antifungal l...

Anglo-Austrian biotech F2G has raised $60.8 million in venture financing to help it bring a drug for life-threatening fungal infections through late-stage development and onto

News

Scepticism as Russia claims coronavirus vaccine breakthrough...

Russia has become the first country in the world to approve a coronavirus vaccine, amid scepticism from international experts who have been unable to review or verify clinical data from the

News

Bayer adds menopause drug to pipeline with KaNDy acquisition

Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline.

News

Roche’s ulcerative colitis drug etrolizumab looks shaky afte...

Roche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans firmly towards the latter.

News

Biogen's shares surge again as FDA hurries Alzheimer's drug ...

Biogen’s Alzheimer’s drug aducanumab could be on the market in the next few months after the FDA accepted a clinical trial dossier and granted a fast Priority Review.

News

BMS’ Opdivo aces trial in asbestos-linked lung cancer

Bristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer, getting one up over rival checkpoint inhibitor Keytr

Novo-backed $61m fundraising helps F2G prep for antifungal l...

Scepticism as Russia claims coronavirus vaccine breakthrough...

Bayer adds menopause drug to pipeline with KaNDy acquisition

Roche’s ulcerative colitis drug etrolizumab looks shaky afte...

Biogen's shares surge again as FDA hurries Alzheimer's drug ...

BMS’ Opdivo aces trial in asbestos-linked lung cancer

Bayer returns to M&A with $2.45bn Perfuse Therapeutics deal

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks